Peer-reviewedLicence not statedPsychopharmacology Bulletin
Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment
Related
- Hepato-Immune Crosstalk Underlies Antipsychotic-Associated Metabolic Dysregulation in Schizophrenia: Quercetin as a Therapeutic Candidate for High-Inflammatory Subtypes.
- The LAI–Oral Antipsychotic Efficacy–Effectiveness Paradox in Schizophrenia
- Baseline severity of positive and negative symptoms predicts relapse in opposing directions among placebo-treated schizophrenia patients: analysis of five placebo-controlled, antipsychotic withdrawal, relapse-prevention trials
- Metabolic syndrome in stable long-term antipsychotic monotherapy and polypharmacy among patients with schizophrenia: a real-world comparative study.
- Sex differences in QTc prolongation and electrocardiographic changes before and after antipsychotic treatment of schizophrenia
BibTeX
@article{hasni2026genetic,
title = {{Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment}},
author = {Dita Hasni and Debie Anggraini and Mutiara Anissa and Lieka Nugrahi Jaslindo},
journal = {Psychopharmacology Bulletin},
year = {2026},
month = oct,
doi = {10.64719/pb.21624},
url = {https://doi.org/10.64719/pb.21624},
}
RIS
TY - JOUR
TI - Genetic Polymorphisms and Hemostatic-Inflammatory Biomarkers in Schizophrenia Patients Receiving Antipsychotic Treatment
AU - Dita Hasni
AU - Debie Anggraini
AU - Mutiara Anissa
AU - Lieka Nugrahi Jaslindo
PY - 2026
DA - 2026/10/30
JO - Psychopharmacology Bulletin
DO - 10.64719/pb.21624
UR - https://doi.org/10.64719/pb.21624
SN - 0048-5764
SN - 2472-2448
ER -